Gilead plans to acquire Ouro Medicines for up to $2.175 billion.

On March 24th, Connoa announced that its NewCo partnership Ouro Medicines has signed an agreement for acquisition with Gilead Sciences. Gilead will acquire Ouro Medicines through the acquisition method, with the transaction amount including a $1.675 billion upfront payment and up to $500 million in milestone payments, for a total transaction amount of up to $2.175 billion. According to the acquisition agreement, as a shareholder of Ouro Medicines, Connoa will receive approximately $250 million in upfront payment and up to $70 million in milestone payments, for a total income of approximately $320 million after the transaction is completed. At the same time, Gilead will assume responsibility for the franchise sales layer of CM336/OM336. After the transaction is completed, Connoa will no longer hold any shares of Ouro Medicines.